CONMED's AirSeal Fix or Crash Deepens on April 29 Earnings Test

The story here is simple: a product failed, the stock crashed, and now everyone is waiting to see if it can recover. CONMED's share price has been in a freefall, down 39% over the past year and trading near its 52-week low of $35.37. That's a brutal drop from its recent highs, wiping out billions in market value. The sell-off has been so severe that even a recent quarterly earnings beat didn't stop the bleeding. The market's verdict is clear-it's not buying the financials if the core product is broken.

The catalyst for this crash is well-documented. In a recent move, Piper Sandler downgraded the stock to Neutral, slashing its price target from $55 to $39. The firm's reasoning is direct: ongoing challenges with the company's AirSeal product and a history of execution missteps have been the primary weight on shares for two years. They see no near-term catalyst to turn things around. This isn't a vague concern; it's a specific diagnosis of a major product struggle.

All eyes are now on the next critical event. CONMED is scheduled to report its first-quarter 2026 financial results after the market close on April 29, 2026. This earnings report is the immediate test. It will show whether the AirSeal issues are contained or if they are spreading to other parts of the business. For a stock that has been punished for a lack of catalysts, this report must provide one. The market will be looking for a clear path forward, not just another set of numbers.

The bottom line is that this isn't a classic value play. The stock is cheap, yes, but that cheapness is a reflection of a real business problem. The decline is a direct result of a major product failure and execution issues, making it a high-risk gamble rather than a simple opportunity. The upcoming earnings call is the first real chance to see if the company can kick the tires on a new plan.

The Real-World Business: Sales Growth vs. Earnings Collapse

The numbers tell a story of two companies. On one side, there's steady sales growth. On the other, a brutal collapse in profitability. That's the real-world health check for CONMED's core operations.

The headline growth is undeniable. For the fourth quarter, sales jumped 7.9% year-over-year. The full-year picture is similar, with revenue up 5.2%. That's the "product still good" argument in action-demand is there. But look closer, and the story changes. The company's bottom line is getting crushed. GAAP earnings per share plunged from $1.08 in Q4 2024 to $0.54 last quarter. That's a 50% cut in a single quarter. The full-year results are even more telling: GAAP EPS fell to $1.51 in 2025 from $4.25 the year before. This isn't a one-quarter blip; it's a structural earnings pressure that has wiped out nearly two-thirds of the company's profit power in just one year.

The geography of the growth adds another layer of concern. While the company's international sales were a bright spot, growing 15.4% in constant currency, domestic revenue barely budged, up just 1.4%. This creates a dependency. The company is leaning heavily on overseas markets to drive top-line growth, which introduces currency and geopolitical risks. It also means the core U.S. business isn't firing on all cylinders.

The bottom line is that you can't ignore the profit collapse. A company can grow sales, but if it's losing money on every dollar, the business model is broken. The sales growth is real, but it's happening while the company's ability to convert that revenue into profit is deteriorating rapidly. For investors, that's the smell test. A product that's truly loved would drive both sales and profits. When sales grow but profits vanish, it usually means costs are out of control or the company is sacrificing margins to stay competitive. In CONMED's case, the evidence points to the latter.

The Valuation Smell Test

So, is the stock a bargain at these prices? The numbers give us a starting point, but the real test is whether they make common sense given the business reality.

The valuation metrics look cheap at first glance. The stock trades at a trailing P/E ratio of 23, which is not a screaming deal. For a company facing clear execution problems and a major product struggle, that multiple is actually on the high side. A truly broken business would command a much lower multiple. This suggests the market is pricing in some hope for a turnaround, but not much.

The analyst view confirms the deep skepticism. The consensus rating is a "Hold", with four out of five analysts giving that cautious verdict. The average price target of $59.80 implies upside, but that target is based on a stock that's already down 39% over the past year. The Hold rating is the real story-it reflects a wait-and-see stance, not a conviction to buy. It's a vote of no confidence in the near-term catalysts.

There is a potential positive note: the company has the financial capacity to pursue tuck-in acquisitions. As one analyst pointed out, CONMED has the ability to do this, which could be a way to grow. But here's the kick-the-tires question: does buying smaller companies fix the core problem of a struggling flagship product? The evidence suggests not. The AirSeal issues have been a two-year drag on shares. Adding more pieces to the puzzle won't solve that if the main product isn't working. It might even distract management from the real fix.

The bottom line is that a low P/E doesn't automatically mean a good investment. When the business model is under pressure and the core product is broken, the cheapness is a warning sign, not an invitation. The valuation here is a reflection of a broken business, not a hidden gem. For now, the numbers don't pass the smell test.

What to Watch: The Path to Recovery

The stock's fate hinges on a few clear, observable signs. The upcoming earnings report is the first major test, but beyond that, investors need to see a credible plan to fix the broken profit engine and a sustainable growth story.

The immediate event is the first-quarter 2026 financial results after the market close on April 29, 2026. This call is the first real chance to see if the AirSeal problems are stabilizing or if they are spreading. The market will be listening for any shift in tone from management. A simple "we're working on it" won't cut it. They need a clear explanation for the brutal Q4 earnings collapse, where GAAP EPS halved. More importantly, they need a credible, step-by-step plan to improve margins. The company's own outlook for 2026 shows a path to adjusted EPS of $4.30-$4.45, which implies a recovery. But that's a target, not a plan. The call must detail how they will get there, especially given the pressure from rising costs and the need to invest in fixing the core product.

Beyond the numbers, the revenue split is a critical health check. The company's growth has been heavily reliant on international markets, where sales jumped 15.4% in constant currency last quarter. That's a positive, but it also means the core U.S. business is weak, with domestic revenue up just 1.4%. For a sustainable recovery, CONMED needs to show it can grow domestically without sacrificing margins. Investors should watch for any signs that the company is regaining traction in its home market, not just leaning on overseas expansion to paper over domestic stagnation.

The bottom line is that recovery requires more than hope. It requires a clear diagnosis of the profit collapse, a believable plan to fix it, and a demonstration that the growth engine isn't just a one-trick pony reliant on international sales. The April 29 report is the first kick at the tires. If the answers aren't solid, the decline may just be getting started.